US court rejects pharma views against new patent rules
This article was originally published in Scrip
Executive Summary
A divided US appeals court has upheld several new patent prosecution rules opposed by the pharmaceutical industry, but the decision leaves the door open to further appellate review and potential invalidation of the regulations on other grounds.